Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization
BACKGROUND: COVID-19 patients present with delirium during their hospitalization.
AIMS: To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors.
METHODS: COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales.
RESULTS: Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).
DISCUSSION: The use of LMWH was associated with absence of delirium, independently of comorbidities and age.
CONCLUSIONS: The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
---|---|
Enthalten in: |
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 42(2021), 4 vom: 13. Apr., Seite 1527-1530 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
D'Ardes, Damiano [VerfasserIn] |
---|
Links: |
---|
Themen: |
9007-41-4 |
---|
Anmerkungen: |
Date Completed 25.03.2021 Date Revised 25.03.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10072-020-04887-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317532758 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317532758 | ||
003 | DE-627 | ||
005 | 20231225163450.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10072-020-04887-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1058.xml |
035 | |a (DE-627)NLM317532758 | ||
035 | |a (NLM)33185785 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a D'Ardes, Damiano |e verfasserin |4 aut | |
245 | 1 | 0 | |a Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2021 | ||
500 | |a Date Revised 25.03.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: COVID-19 patients present with delirium during their hospitalization | ||
520 | |a AIMS: To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors | ||
520 | |a METHODS: COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales | ||
520 | |a RESULTS: Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006) | ||
520 | |a DISCUSSION: The use of LMWH was associated with absence of delirium, independently of comorbidities and age | ||
520 | |a CONCLUSIONS: The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a C reactive protein | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Delirium | |
650 | 4 | |a Low molecular weight heparin | |
650 | 7 | |a Anticoagulants |2 NLM | |
650 | 7 | |a Enoxaparin |2 NLM | |
650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
650 | 7 | |a C-Reactive Protein |2 NLM | |
650 | 7 | |a 9007-41-4 |2 NLM | |
700 | 1 | |a Carrarini, Claudia |e verfasserin |4 aut | |
700 | 1 | |a Russo, Mirella |e verfasserin |4 aut | |
700 | 1 | |a Dono, Fedele |e verfasserin |4 aut | |
700 | 1 | |a Speranza, Rino |e verfasserin |4 aut | |
700 | 1 | |a Digiovanni, Anna |e verfasserin |4 aut | |
700 | 1 | |a Martinotti, Giovanni |e verfasserin |4 aut | |
700 | 1 | |a Di Iorio, Angelo |e verfasserin |4 aut | |
700 | 1 | |a Onofrj, Marco |e verfasserin |4 aut | |
700 | 1 | |a Cipollone, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Bonanni, Laura |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |d 2000 |g 42(2021), 4 vom: 13. Apr., Seite 1527-1530 |w (DE-627)NLM108608468 |x 1590-3478 |7 nnns |
773 | 1 | 8 | |g volume:42 |g year:2021 |g number:4 |g day:13 |g month:04 |g pages:1527-1530 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10072-020-04887-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 42 |j 2021 |e 4 |b 13 |c 04 |h 1527-1530 |